Sign Up to like & get
recommendations!
1
Published in 2017 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2017-071
Abstract: The FDA has approved one PD-1 checkpoint inhibitor, pembrolizumab, and two PD-L1 checkpoint inhibitors, avelumab and durvalumab, to treat metastatic urothelial carcinoma in patients whose disease continues to progress despite platinum-based chemotherapy. This brings the…
read more here.
Keywords:
drugs approved;
approved urothelial;
carcinoma;
carcinoma fda ... See more keywords